Severe Head Injury Brain Analysis
Launched by QUEEN MARY UNIVERSITY OF LONDON · Jan 24, 2022
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
A minor amendment was submitted to allow histological and immunohistochemical analysis of the samples.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Severe traumatic brain injury -
- • Exclusion Criteria: Coagulopathy
- • -
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Chris E Uff, PhD
Principal Investigator
Queen Mary University of London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials